On the one hand, flIL-33 affects lung fibrosis by modulating the innate immune landscape, directly or indirectly increasing the presence of MCP-1/CCL2, IL-6, TGF-β1 and DAMPs such as HSP70, independently of ST2, IL4 or IL-13 (179). This evidence concerns the gene IL4 and pulmonary fibrosis.